Rat model of influenza-associated encephalopathy (IAE): studies of electroencephalogram (EEG) in vivo

Cissé, Youssouf; Wang, S.; Inoue, Isao; Kido, Hiroshi

doi:10.1016/j.neuroscience.2009.10.062

Cited by 12 publications

(24 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytokine elevation was also noted in case reports of acute encephalopathy and ANE [30,72,76], and elevation of IL-6 was shown to mirror abnormal EEG changes in influenzainfected rats with induced hyperthermia [107]. [16,116] or raised cytokine levels [46], and may result in mild CNS disorders in some younger patients [117][118][119] [128].…”

Section: Genetic Influencesmentioning

confidence: 79%

Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review

Toovey

Prinssen

Rayner³

et al. 2012

Adv Therapy

View full text Add to dashboard Cite

A 2008 review by our group concluded that the risk of neuropsychiatric adverse events (NPAEs) in influenza patients was not increased by oseltamivir exposure, and did not identify any mechanism by which oseltamivir or its metabolites could cause or worsen such events. The current article reviews new information on this topic. Between September 16, 2007 and May 15, 2010, 1,805 spontaneously-reported NPAEs were identified in 1,330 patients receiving oseltamivir: 767 (42.5%) from Japan, 296 (16.4%) from the USA, and 742 (41.1%) from other countries. NPAEs were more common in children: 1,072 (59.4%) events were in those aged ≤16 years. NPAEs often occurred within 48 h of treatment initiation (953 events; 52.8%). Nearly half of the events were serious in nature (838; 46.4%). The three largest categories of events were abnormal behavior (457 events, 25.3%), miscellaneous psychiatric events (370; 20.5%), and delusions/perceptual disturbances (316 events, 17.5%). A total of 1,545 events (85.6%) in eight different categories were considered to be delirium or delirium-like. Twenty-eight suicide-related events were reported. A US healthcare claims database analysis showed that the risk of NPAEs in 7,798 oseltamivir-treated patients was no higher than that in 10,411 patients not on antivirals, but a study on oseltamivir and abnormal behavior in Japan was less conclusive. NPAE frequency in oseltamivir-exposed Japanese and Taiwanese children with influenza was the same as in unexposed children. New analysis of the UK General Practice Research Database showed that the relative adjusted risk of NPAEs in influenza patients was 2.18-times higher than in the general population. Other epidemiology studies report frequent occurrence of encephalitis and similar disorders in influenza patients independently of oseltamivir exposure. The new data support the findings of the original assessment. Evidence suggests that influenza-related encephalopathies are caused by influenza-induced inflammatory responses, but more work is needed to confirm the underlying mechanisms.

show abstract

Section: Genetic Influencesmentioning

confidence: 79%

Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review

Toovey

Prinssen

Rayner³

et al. 2012

Adv Therapy

View full text Add to dashboard Cite

show abstract

“…The most important objectives in treating infants with influenza are short time to stabilization and the prevention of serious complications. In Japan, there have been many reports of influenza-associated encephalopathy and encephalitis, and in about 50% of these cases, the event developed into a serious condition [2][3][4][5][6][7][8][9].…”

Section: Discussionmentioning

confidence: 99%

“…It has recently been reported that the mechanism of diseases such as influenza-associated encephalopathy or myocarditis leading to sudden death may be mediated by the release of cytokines as a result of high fever, causing damage to the vascular endothelium of the central nervous system [4][5][6][7]10]. Moreover, it was confirmed using an animal model that influenza viral infection and fever have an effect on the hippocampus, and the mechanism of neuropsychiatric disorders such as delirium is being further elucidated [4,6,7]. It is also becoming evident that most of the symptoms suspected to have been triggered by oseltamivir administration were caused by the influenza virus infection itself.…”

Section: Discussionmentioning

confidence: 99%

Safety of oseltamivir in infants less than one year old: Prospective surveillance during the 2004–2005 influenza season in Japan

Tahara¹,

Asano

Mitamura

et al. 2015

J Pediatr Infect Dis

View full text Add to dashboard Cite

The aim of this study was to investigate the treatment of influenza and safety of oseltamivir in infants less than 1 year of age. All-patient surveillance was conducted using centralized enrolment at 219 medical institutions. Safety data were collected for 1,663 patients less than 1 year of age who developed influenza during the 2004-2005 influenza season. Patients were stratified into three groups: patients not treated with a drug (Group A), patients treated with oseltamivir (Group B), and patients treated with a drug other than an antiviral agent (Group C). Significant differences (P = 0.0074, P < 0.0001) were observed among incidences of adverse events in the three groups (Group A: 26.7%, Group B: 30.0%, Group C: 21.5%) and between the incidences of adverse drug reactions (ADRs) in the two drug-treated groups (Group B: 6.7%, Group C: 0.9%). The most commonly reported ADRs in patients treated with oseltamivir were diarrhoea, hypothermia, vomiting, and rash. We found that 77.2% of patients received oseltamivir and 20.0% received symptomatic treatments such as antipyretic agents. In infants less than 1 year of age, incidence of ADRs with oseltamivir treatment was higher than with symptomatic treatments, however these ADRs were treatable symptoms and consistent with the ADRs reported in young children treated with oseltamivir. Our analysis of the safety of oseltamivir in infants less than 1 year of age revealed clinical acceptance of safety issues.

show abstract

“…EEG in acute encephalopathy generally reveals a slowing of background frequencies with or without the presence of TWs and frontal intermittent rhythmic delta activity (FIRDA) (Accolla et al, 2011;Cisse et al, 2010;Gloor et al, 1977). These patterns are widely believed to reflect an underlying structural or metabolic problem.…”

Section: Eeg Patterns In Encephalopathy and Deliriummentioning

confidence: 99%

Clinical and Electroencephalographic Correlates of Acute Encephalopathy

Sutter

Kaplan

2013

Journal of Clinical Neurophysiology

View full text Add to dashboard Cite

The term encephalopathy encompasses a wide variety of syndromes caused by a large number of different toxic, metabolic, and degenerative derangements. Despite advances in intensive medical care and new diagnostic procedures, encephalopathy remains a frequent and underrecognized critical medical condition with high morbidity and mortality. Electroencephalography (EEG) enables rapid bedside electrophysiological measurements of brain dysfunction and complements clinical and neuroimaging assessment of encephalopathic patients. Both progressive slowing of EEG background activity with increasing cerebral compromise and decreased EEG reactivity to external stimuli provide important diagnostic and prognostic information. The aim of this review was to provide an overview of the diagnostic and prognostic value of EEG in encephalopathic patients.

show abstract

Rat model of influenza-associated encephalopathy (IAE): studies of electroencephalogram (EEG) in vivo

Cited by 12 publications

References 41 publications

Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review

Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review

Safety of oseltamivir in infants less than one year old: Prospective surveillance during the 2004–2005 influenza season in Japan

Clinical and Electroencephalographic Correlates of Acute Encephalopathy

Contact Info

Product

Resources

About